Invesaro

Stocks Comparison

HeartSciences vs Solana: revenue, profit, margins and growth compared

HeartSciences brought in $4.3K of revenue in fiscal 2026, Solana $6M in fiscal 2025. Revenue changed by -0.7% at HeartSciences and +1,057.1% at Solana on the year before, so Solana grew faster. HeartSciences kept -211,666.5% of its revenue as net profit, Solana -679.6%.

Side by side, latest fiscal year

HSCSHSDT
Fiscal year endedFY2026 (April 30, 2026)FY2025 (December 31, 2025)
Revenue$4.3K$6M
Revenue growth-0.7%+1,057.1%
Net income-$9.1M-$40.9M
Net margin-211,666.5%-679.6%
Free cash flow-$7.4Mn/a
Free cash flow margin-172,036.6%n/a
Earnings per share (diluted)-$3.48-$1.85
Cash$1.7M$7.3M
Debtn/an/a
Price to earningsn/an/a
Market value$18.4M$177.7M
Dividend yieldn/an/a
Rank by revenue in sector#646 of 646 · Health care#504 of 646 · Health care

Over the years

Revenue
HSCS FY2023: $14.4KHSCS FY2023: $5.2KHSCS FY2024: $18.6KHSCS FY2025: $4.4KHSCS FY2026: $4.3KHSDT FY2018: $478KHSDT FY2019: $1.5MHSDT FY2020: $661KHSDT FY2021: $522KHSDT FY2022: $787KHSDT FY2023: $644KHSDT FY2024: $520KHSDT FY2025: $6MFY18FY19FY20FY21FY22FY23FY24FY25FY26
HSCS $4.3KHSDT $6M
Net income
HSCS FY2023: -$4.8MHSCS FY2023: -$6.4MHSCS FY2024: -$6.6MHSCS FY2025: -$8.8MHSCS FY2026: -$9.1MHSDT FY2018: -$28.6MHSDT FY2019: -$9.8MHSDT FY2020: -$14.1MHSDT FY2021: -$18.1MHSDT FY2022: -$14.1MHSDT FY2023: -$8.9MHSDT FY2024: -$11.7MHSDT FY2025: -$40.9MFY18FY19FY20FY21FY22FY23FY24FY25FY26
HSCS -$9.1MHSDT -$40.9M
Net margin
HSCS FY2023: -33,592.6%HSCS FY2023: -123,384.3%HSCS FY2024: -35,511.9%HSCS FY2025: -201,499.5%HSCS FY2026: -211,666.5%HSDT FY2018: -5,988.1%HSDT FY2019: -653.8%HSDT FY2020: -2,137.7%HSDT FY2021: -3,473.6%HSDT FY2022: -1,788.1%HSDT FY2023: -1,374.2%HSDT FY2024: -2,258.1%HSDT FY2025: -679.6%FY18FY19FY20FY21FY22FY23FY24FY25FY26
HSCS -211,666.5%HSDT -679.6%
Revenue growth
HSCS FY2023: -64.2%HSCS FY2024: +261.2%HSCS FY2025: -76.6%HSCS FY2026: -0.7%HSDT FY2019: +213.0%HSDT FY2020: -55.8%HSDT FY2021: -21.0%HSDT FY2022: +50.8%HSDT FY2023: -18.2%HSDT FY2024: -19.3%HSDT FY2025: +1,057.1%FY19FY20FY21FY22FY23FY24FY25FY26
HSCS -0.7%HSDT +1,057.1%
Free cash flow
HSCS FY2023: -$3.6MHSCS FY2023: -$5.8MHSCS FY2024: -$6.1MHSCS FY2025: -$7.4MHSCS FY2026: -$7.4MHSDT FY2018: -$20.1MHSDT FY2019: -$21.3MHSDT FY2020: -$11.8MHSDT FY2021: -$13.4MHSDT FY2022: -$14.3MHSDT FY2023: -$10.4MHSDT FY2024: -$11MFY18FY19FY20FY21FY22FY23FY24FY25FY26
HSCS -$7.4MHSDT -$11M

Fiscal years as each company reports them; the two may end in different months.

Questions about HeartSciences and Solana

Which is bigger by revenue, HeartSciences or Solana?

Solana is bigger by revenue: $6M in fiscal 2025, against $4.3K for HeartSciences in fiscal 2026.

Which keeps more of its revenue as profit, HeartSciences or Solana?

HeartSciences had a net margin of -211,666.5% in fiscal 2026; Solana had -679.6% in fiscal 2025.

Which grew revenue faster, HeartSciences or Solana?

In their latest fiscal years revenue changed by -0.7% at HeartSciences and +1,057.1% at Solana.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies